{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:16:38Z","timestamp":1770524198968,"version":"3.49.0"},"reference-count":23,"publisher":"Japanese Society of Toxicology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2131\/jts.39.1","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T23:03:40Z","timestamp":1389308620000},"page":"1-6","source":"Crossref","is-referenced-by-count":62,"title":["New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron"],"prefix":"10.2131","volume":"39","author":[{"given":"Asuka","family":"Kaizaki","sequence":"first","affiliation":[{"name":"Division of Toxicology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Toxicology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Numazawa","sequence":"additional","affiliation":[{"name":"Division of Toxicology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Angoa-P&eacute;rez, M., Kane, M.J., Francescutti, D.M., Sykes, K.E., Shah, M.M., Mohammed, A.M., Thomas, D.M. and Kuhn, D.M. (2012): Mephedrone, an abused psychoactive component of &lsquo;bath salts&rsquo; and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J. Neurochem., <b>120<\/b>, 1097-1107.","DOI":"10.1111\/j.1471-4159.2011.07632.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Brandt, S.D., Sumnall, H.R., Measham, F. and Cole, J. (2010): Analyses of second-generation &lsquo;legal highs&rsquo; in the UK: initial findings. Drug Test Anal., <b>2<\/b>, 377-382.","DOI":"10.1002\/dta.155"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Callahan, J.W. and Abercrombie, E.D. (2011): <i>In vivo<\/i> dopamine efflux is decreased in striatum of both fragment (R6\/2) and full-length (YAC128) transgenic mouse models of Huntington&rsquo;s disease. Front Syst. Neurosci., <b>5<\/b>, 61.","DOI":"10.3389\/fnsys.2011.00061"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Carroll, F.I., Blough, B.E., Mascarella, S.W., Navarro, H.A., Eaton, J.B., Lukas, R.J. and Damaj, M.I. (2010): Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J. Med. Chem., <b>53<\/b>, 2204-2214.","DOI":"10.1021\/jm9017465"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Cozzi, N.V., Sievert, M.K., Shulgin, A.T., Jacob, P.3rd. and Ruoho, A.E. (1999): Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur. J. Pharmacol., <b>381<\/b>, 63-69.","DOI":"10.1016\/S0014-2999(99)00538-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Damaj, M.I., Carroll, F.I., Eaton, J.B., Navarro, H.A., Blough, B.E., Mirza, S., Lukas, R.J. and Martin, B.R. (2004): Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol., <b>66<\/b>, 675-682.","DOI":"10.1124\/mol.104.001313"},{"key":"7","doi-asserted-by":"crossref","unstructured":"den Hollander, B., Rozov, S., Linden, A.M., Uusi-Oukari, M., Ojanper&auml;, I. and Korpi, E.R. (2013): Long-term cognitive and neurochemical effects of &ldquo;bath salt&rdquo; designer drugs methylone and mephedrone. Pharmacol. Biochem. Behav., <b>103<\/b>, 501-509.","DOI":"10.1016\/j.pbb.2012.10.006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Fleckenstein, A.E., Gibb, J.W. and Hanson, G.R. (2000): Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol., <b>406<\/b>, 1-13.","DOI":"10.1016\/S0014-2999(00)00639-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Glennon, R.A., Yousif, M., Naiman, N. and Kalix, P. (1987): Methcathinone: a new and potent amphetamine-like agent. Pharmacol. Biochem. Behav., <b>26<\/b>, 547-551.","DOI":"10.1016\/0091-3057(87)90164-X"},{"key":"10","unstructured":"James, D., Adams, R.D., Spears, R., Cooper, G., Lupton, D.J., Thompson, J.P. and Thomas, S.H. (2011): National Poisons Information Service. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg. Med. J., <b>28<\/b>, 686-689."},{"key":"11","doi-asserted-by":"crossref","unstructured":"Kalix, P. (1992): Cathinone, a natural amphetamine. Pharmacol. Toxicol., <b>70<\/b>, 77-86.","DOI":"10.1111\/j.1600-0773.1992.tb00434.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Marinetti, L.J. and Antonides, H.M. (2013): Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J. Anal. Toxicol., <b>37<\/b>, 135-146.","DOI":"10.1093\/jat\/bks136"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Marusich, J.A., Grant, K.R., Blough, B.E. and Wiley, J.L. (2012): Effects of synthetic cathinones contained in &ldquo;bath salts&rdquo; on motor behavior and a functional observational battery in mice. Neurotoxicology, <b>33<\/b>, 1305-1313.","DOI":"10.1016\/j.neuro.2012.08.003"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Meltzer, P.C., Butler, D., Deschamps, J.R. and Madras, B.K. (2006): 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem., <b>49<\/b>, 1420-1432.","DOI":"10.1021\/jm050797a"},{"key":"15","unstructured":"Numazawa, S. (2013): The forefront of drug abuse &#8211;Recent trends in illegal drugmarkets in Japan, 2012-. Showa Univ. J. Pharmaceut. Sci., <b>4<\/b>, 13-25."},{"key":"16","doi-asserted-by":"crossref","unstructured":"Pierce, R.C. and Kalivas, P.W. (1997): A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Brain Res. Rev., <b>25<\/b>, 192-216.","DOI":"10.1016\/S0165-0173(97)00021-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Rothman, R.B., Baumann, M.H., Dersch, C.M., Romero, D.V., Rice, K.C., Carroll, F.I. and Partilla, J.S. (2001): Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, <b>39<\/b>, 32-41.","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Sauer, C., Peters, F.T., Haas, C., Meyer, M.R., Fritschi, G. and Maurer, H.H. (2009): New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic\/mass spectrometric techniques. J. Mass. Spectrom., <b>44<\/b>, 952-964.","DOI":"10.1002\/jms.1571"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Vazquez, J.F., Clement, H.W., Sommer, O., Schulz, E. and van Calker, D. (2008): Local stimulation of the adenosine A2B receptors induces an increased release of IL-6 in mouse striatum: an <i>in vivo<\/i> microdialysis study. J. Neurochem., <b>105<\/b>, 904-909.","DOI":"10.1111\/j.1471-4159.2007.05191.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"White, F.J. and Kalivas, P.W. (1998): Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend., <b>51<\/b>, 141-153.","DOI":"10.1016\/S0376-8716(98)00072-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Widler, P., Mathys, K., Brenneisen, R., Kalix, P. and Fisch, H.U. (1994): Pharmacodynamics and pharmacokinetics of khat: a controlled study. Clin. Pharmacol. Ther., <b>55<\/b>, 556-562.","DOI":"10.1038\/clpt.1994.69"},{"key":"22","unstructured":"Winstock, A.R., Mitcheson, L.R., Deluca, P., Davey, Z., Corazza, O. and Schifano, F. (2011): Mephedrone, new kid for the chop? Addiction., <b>106<\/b>, 154-161."},{"key":"23","doi-asserted-by":"crossref","unstructured":"Zhang, L., Kitaichi, K., Fujimoto, Y., Nakayama, H., Shimizu, E., Iyo, M. and Hashimoto, K. (2006): Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog. Neuropsychopharmacol. Biol. Psychiatry, <b>30<\/b>, 1381-1393.","DOI":"10.1016\/j.pnpbp.2006.05.015"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/39\/1\/39_1\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T23:46:00Z","timestamp":1716421560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/39\/1\/39_1\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.39.1","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}